Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer Read more about Genomics in Michigan to AdJust Outcomes in Prostate canceR (G-MAJOR) for Men With Newly Diagnosed Favorable Risk Prostate Cancer
ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States Read more about ADSTILADRIN Early Utilization and Outcomes in the Real World Setting in the United States
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score Read more about Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial Read more about Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Read more about A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT
Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors Read more about Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) Read more about PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001)
Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations Read more about Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Read more about A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA-2
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC Read more about Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC